Autopsy report · NCT04663386

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway

“Target recruitment not reached”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 29 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Orion Corporation, Orion Pharma

Sponsor type

Industry

Conditions

Asthma; COPD

Interventions

Budesonide-Formoterol

Participants

29

Sites

1

Countries

Norway

Trials that died the same way

• Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis
  “Not able to meet recruitment targets” (89% match in meaning)
• Efficacy and Safety of MedifoamⓇ and BetafoamⓇ in Pressure Ulcer
  “Difficulties in meeting recruitment target” (85% match in meaning)
• Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study
  “Difficulty with meeting recruitment targets” (83% match in meaning)
• Opioid Reduction Following Spinal Cord Stimulation
  “Site did not meet recruitment goals and target numbers” (81% match in meaning)
• Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)
  “Unable to achieve recruitment target.” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.